Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479388 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479198 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL37559 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL672371 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL671456 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL4619726 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL4619498 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479563 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479610 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL1576782 | 0.96 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| EP-3458092-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| WO-2017201352-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201350-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4577520-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024216162-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024044728-A1 | PEGYLATED LIPID COMPOUNDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023240261-A1 | NUCLEOBASE EDITING SYSTEM AND METHOD OF USING SAME FOR MODIFYING NUCLEIC ACID SEQUENCES | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2021030769-A1 | EXTRACELLULAR VESICLES WITH NRAS ANTISENSE OLIGONUCLEOTIDES | CODIAK BIOSCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-3740211-A1 | TREATING MICROVASCULAR DYSFUNCTION | Endoprotech, Inc (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3458474-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201352-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201325-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-2968145-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | Mallinckrodt LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160392-A1 | MODIFIED DOCETAXEL LIPOSOME FORMULATIONS | MALLINCKRODT LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2410990-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | Marval Biosciences, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010107990-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CONTRAST IN IMAGING | MARVAL BIOSCIENCES, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2006130177-A1 | PARTICULATE-STABILIZED INJECTABLE PHARMACEUTICAL COMPOSITIONS OF POSACONAZOLE | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |